Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC for Treatment of ICU COVID-19 Patients - Seite 4

Media and Investor Relations

Contact: Alexis Nahama, DVM (SVP Corporate Development)

Telephone: [phone]

Email: [e-mail]

Sorrento and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

G-MAB, DAR-T, COVI-GUARD, COVI-AMG, COVI-SHIELD, Gene-MAb, COVI-DROPS, COVI-MSC, COVI-TRACK, COVI-TRACE and COVI-STIX are trademarks of Sorrento Therapeutics, Inc.

SEMDEXA is a trademark of Semnur Pharmaceuticals, Inc.

ZTlido is a trademark owned by Scilex Pharmaceuticals Inc.

All other trademarks are the property of their respective owners.

2021 Sorrento Therapeutics, Inc. All Rights Reserved.